time to definitive deterioration of GHS/QoL
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Naoto T Ueno, Francesco Cottone, Kyle Dunton, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Aleix Prat, Junji Tsurutani, Yeon Hee Park, Hope S Rugo, Binghe Xu, Fatima Cardoso, Zahi Mitri, Reshma Mahtani, Cecilia Orbegoso Aguilar, Feng Xiao, Nadia Harbeck, David A Cameron, Shanu Modi
Oncologist 30(5) oyaf048
BACKGROUND: The phase 3 DESTINY-Breast04 trial demonstrated superior efficacy and acceptable safety with trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy in previously treated patients with human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). We report the patient-reported outcomes (PROs), focusing on the hormone receptor-positive cohort. PATIENTS AND METHODS: Patients were randomized 2:1 to T-DXd (5.4 mg/kg intravenously every 3 weeks) or physician's choice of chemotherapy and prospectively assessed for PRO measures. Change from baseline and time to definitive deterioration (TDD) were calculated from the EORTC QLQ-C30 and QLQ-BR45 and the EQ-5D-5L questionnaires. RESULTS: Baseline global health status/quality of life (GHS/QoL) scores were similar between groups (T-DXd, 331 patients; physician's choice, 163 patients); there were no clinically meaningful changes while on either treatment (median duration: T-DXd, 8.2 months; physician's choice, 3.5 months). Median TDD for GHS/QoL was delayed with T-DXd vs physician's choice (11.4 vs 7.5 months, respectively; hazard ratio, 0.69; 95% CI, 0.52-0.92). Median TDD for all prespecified PROs, including pain, favored T-DXd. In an additional analysis, the median TDD was shorter for nausea and vomiting with T-DXd vs the physician's choice. CONCLUSIONS: Trastuzumab deruxtecan maintained GHS/QoL scores despite a longer treatment course compared with standard chemotherapy and delayed definitive deterioration across all prespecified PROs vs the physician's choice. Appropriate management of adverse events and use of preventive measures (ie, antiemetic prophylaxis) may further support patient health-related quality of life. These findings reinforce the benefit of T-DXd as an option for patients with HER2-low mBC. ClinicalTrials.gov: NCT03734029.
1 个 Figure · 3 个 KM 面板
Figure 3. Kaplan-Meier plot of time to definitive deterioration of (A) GHS/QoL, (B) pain, and (C) physical functioning with T-DXd and physician’s choice of chemotherapy in the HR+ cohort. EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; physician’s choice, physician’s choice of chemotherapy; PRO, patient-reported outcome; QLQ-C30, Quality of Life Core 30 questionnaire; QoL, quality of life; TDD, time to definitive deterioration; T-DXd, trastuzumab deruxtecan. GHS/QoL, pain symptoms, and physical functioning are scales of the EORTC QLQ-C30. Clinically meaningful definitive deterioration was defined as a change of ≥ 10 points from baseline at either 2 or more consecutive time points, last PRO assessment, or death by the first survival follow-up visit. a Nominal P value not adjusted for multiple testing. b All patients were included in the analysis; patients without baseline assessments were censored per the statistical analysis plan.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。